Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

Perspective Therapeutics, Inc.

Contributing Author

Recent Articles by Perspective Therapeutics, Inc.

Nov-20	Perspective Therapeutics to Participate in Upcoming December Conferences CATX GlobeNewswire
Nov-10	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results CATX GlobeNewswire
Oct-31	Perspective Therapeutics to Participate in Upcoming November Conferences CATX GlobeNewswire
Oct-24	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results CATX GlobeNewswire
Oct-20	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025 CATX GlobeNewswire
Oct-02	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors CATX GlobeNewswire
Sep-15	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma CATX GlobeNewswire
Sep-04	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer CATX GlobeNewswire
Sep-03	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors CATX GlobeNewswire
Aug-26	Perspective Therapeutics to Participate in Upcoming September Conferences CATX GlobeNewswire
Aug-13	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results CATX GlobeNewswire
Jul-24	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 CATX GlobeNewswire
Jul-15	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results CATX GlobeNewswire
Jun-21	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial CATX GlobeNewswire
Jun-21	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting CATX GlobeNewswire
May-30	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting CATX GlobeNewswire
May-12	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results CATX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.